MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression

Gene

Volumn 493, Issue 1, 2012, Pages 44-51

  Zhong, Xiang Yu ^a   Yu, Jian Hua ^a   Zhang, Wei Guang ^b   Wang, Zhi Dong ^a   Dong, Qin ^b   Tai, Sheng ^a   Cui, Yun Fu ^a   Li, Hui ^b  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Biliary malignancy; Cell cycle arrest; Cholangiocarcinoma; Gallbladder cancer; MiR 421; Tumor suppressor gene

Indexed keywords

FARNESOID X RECEPTOR; MICRORNA 421; RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIARY TRACT CANCER; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; UPREGULATION;

BILIARY TRACT NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 84655169703     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.11.028     Document Type: Article

References (30)

1. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J., Suchy F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 2001, 276:28857-28865.
2. Blechacz B., Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48:308-321.
3. Chureau C., et al. Ftx is a non-coding RNA which affects Xist expression and chromatin structure within the X-inactivation center region. Hum. Mol. Genet. 2011, 20:705-718.
4. De Gottardi A., et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig. Dis. Sci. 2004, 49:982-989.
5. de Groen P.C., Gores G.J., LaRusso N.F., Gunderson L.L., Nagorney D.M. Biliary tract cancers. N. Engl. J. Med. 1999, 341:1368-1378.
6. Dong Z., Cmarik J.L. Harvesting cells under anchorage-independent cell transformation conditions for biochemical analyses. Sci. STKE 2002, 2002:pl7.
7. Esquela-Kerscher A., Slack F.J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
8. Guo J., et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J. Gastroenterol. Hepatol. 2009, 24:652-657.
9. Hao J., Zhang S., Zhou Y., Liu C., Hu X., Shao C. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochem. Biophys. Res. Commun. 2011, 406:552-557.
10. Hu H., Du L., Nagabayashi G., Seeger R.C., Gatti R.A. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1506-1511.
11. Jarnagin W.R., Shoup M. Surgical management of cholangiocarcinoma. Semin. Liver Dis. 2004, 24:189-199.
12. Jiang S., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70:3119-3127.
13. Joo J.H., Jetten A.M. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett. 2010, 287:123-135.
14. Khan S.A., Thomas H.C., Davidson B.R., Taylor-Robinson S.D. Cholangiocarcinoma. Lancet 2005, 366:1303-1314.
15. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
16. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
17. Malhi H., Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J. Hepatol. 2006, 45:856-867.
18. Meng F., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
19. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
20. Nakeeb A., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 1996, 224:463-473. discussion 473-5.
21. Obama K., et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 2005, 41:1339-1348.
22. Ostling P., et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011, 71:1956-1967.
23. Selaru F.M., et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009, 49:1595-1601.
24. Shaib Y., El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 2004, 24:115-125.
25. Stefani G., Slack F.J. Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell Biol. 2008, 9:219-230.
26. Swales K.E., Korbonits M., Carpenter R., Walsh D.T., Warner T.D., Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 2006, 66:10120-10126.
27. Wang Y.D., Chen W.D., Moore D.D., Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008, 18:1087-1095.
28. Werneburg N.W., Yoon J.H., Higuchi H., Gores G.J. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G31-G36.
29. Yang F., Huang X., Yi T., Yen Y., Moore D.D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67:863-867.
30. Zhou L., et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 2008, 264:209-217.